Close Menu

NEW YORK – Thermo Fisher Scientific said on Monday that it has priced an offering of €1.2 billion ($1.33 billion) worth of euro-denominated senior notes.

The Waltham, Massachusetts-based company is offering €6 billion worth of senior notes with an interest rate of 1.75 percent per year and a due date of 2027, and €6 billion worth of senior notes with an interest rate of 2.375 percent per year and a due date of 2032.

The offering is expected to close on or about April 2, subject to customary closing conditions, and the notes will pay interest on an annual basis.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.